• Geneoscopy

  Participated · Series C · Jan 2025

  Geneoscopy leverages a proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform to develop diagnostic tests for gastrointestinal diseases. Its lead product, ColoSense, is an FDA-approved at-home, stool-based colorectal cancer screening test for average-risk individuals over age 45. The company pairs its RNA isolation platform with Bio-Rad’s Droplet Digital PCR (ddPCR) technology to achieve high sensitivity and specificity. Geneoscopy plans to launch and commercialize ColoSense and is working with Labcorp to provide broad availability so providers can order the test within screening programs. The firm is also investing in an innovative pipeline of diagnostic tests for inflammatory bowel disease, including tools for treatment selection and therapy monitoring. The recent financing is positioned to support commercialization, regulatory milestones, and continued product development. Geneoscopy is a St. Louis, MO–based life sciences company focused on developing diagnostic tests for gastrointestinal health. Its lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. The device was awarded Breakthrough Device Designation from the US FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Preliminary trials suggest the diagnostic can detect these lesions at a higher rate than existing noninvasive screening tests. The company intends to use recent funding to support the U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand its diagnostic product pipeline. Andrew Barnell is the company's CEO. Geneoscopy is a life sciences company focused on developing diagnostic tests for gastrointestinal (GI) health. Its lead product is a colorectal cancer (CRC) screening test that quantifies eukaryotic RNA isolated from epithelial cells in stool to detect CRC and advanced adenomas. The company announced an oversubscribed $6.9 million Series A and plans to use the proceeds to advance the CRC screening test. The financing was led by Cultivation Capital and NT Investments, with Lightchain Capital LLC as a significant investor. Following the round, Bobby W. Sandage, Jr., Najeeb Thomas, and Drew Dennison are joining Geneoscopy’s board of directors. Geneoscopy highlights that stool-derived eukaryotic RNA biomarkers are highly sensitive for both cancer and precancerous lesions, and it intends to pursue other applications of its platform technology.

• Nucleus RadioPharma

  Participated · Series A · Oct 2023

  Nucleus RadioPharma manufactures radiopharmaceuticals and manages the time-sensitive logistics required to deliver those radioactive cancer therapies to hospitals before they decay. Founded in late 2022 and launched in 2023 with a $56 million Series A, the company opened its Rochester manufacturing facility on the Mayo Clinic campus and plans a second regional hub outside Philadelphia. Its strategy centers on expanding regional manufacturing capacity to address supply-chain bottlenecks caused by short half-lives of radioactive isotopes. The recent $50 million financing from OrbiMed will fund further expansion at Rochester and construction of the Philadelphia-area site. Nucleus currently employs 56 full-time staff and is hiring as it ramps toward full operations, aiming to have the new regional center operational by 2028.

• Lucem Health

  Led · Series A · May 2023

  Lucem Health is a provider of clinical AI technology and solutions that helps innovators transform data science into deployable clinical tools. The company recently launched Lucem Health Reveal, a family of solutions that identify patients at higher risk of serious or chronic diseases using readily available clinical data. Its platform is designed for clinical AI solution deployment to surface previously undiscovered insights that support earlier disease detection and optimized treatment delivery. Led by CEO Sean Cassidy and based in Davidson, NC, Lucem Health intends to use new funding to advance platform development and grow its solution portfolio. The company also plans to expand its sales and marketing capacity to drive adoption among physicians and providers. Financially, Lucem Health completed a $7.7M Series A in 2023 led by Mayo Clinic, Granger Management, and Mercy, with participation from existing investor Rally Ventures.

• Unite Us

  Participated · Series A · Aug 2015

  Unite Us provides the digital infrastructure to power an integrated health and social care ecosystem. It builds coordinated care networks enabling providers to send and receive secure electronic referrals, track each person's total health journey, and report on tangible outcomes across services. The company has signed hundreds of partners nationwide, including Kaiser Permanente, CyncHealth, the state of North Carolina, the Commonwealth of Virginia, Humana, CommonSpirit Health, CVS Aetna, the Cleveland Clinic, and United Ways. Led by co-founders Dan Brillman (CEO) and Taylor Justice (President), Unite Us expanded into 42 states in 2020, adding 16 new statewide networks. In March 2021 it raised $150M in a Series C at a valuation above $1.6 billion and intends to use the funds to invest in Unite Us Payments and further develop its interoperability framework. Unite Us builds an outcome-focused technology platform that connects healthcare and social service providers into coordinated networks to send referrals, track individual outcomes, and integrate social determinants of health into patient care. The platform enables providers across the service continuum to interconnect around each patient, centralize reporting on tangible outcomes, and move beyond legacy resource directories. Unite Us began in 2013 serving the military-connected population and has expanded to serve Medicaid and Medicare beneficiaries, the homeless, justice-involved individuals, and people with behavioral health and substance-use challenges. The company is headquartered in New York City with offices in Raleigh and Portland. Financially, Unite Us announced a $35 million Series B and has raised $45.3 million in total funding to date. Management says the capital will fund growth, new products and innovations, and broader integration of social care into value-based payment models. The company plans to leverage its outcome data for predictive analytics and to drive payment reform and service integration across communities. Unite US operates UniteUS.com, a free resource network connecting current military service members, veterans and their families to local resources and opportunities. It provides organizations and communities with cloud-based organizational and care coordination software tools to communicate and manage services. The company powers NYC Serves, a coordinated network in New York City with over 40 public and private organizations and roughly 200 practitioners delivering coordinated care for the city's military population. Unite US reports upwards of 100,000+ users on its consumer platform and over 1,000 users accessing its software. Led by CEO Dan Brillman, the company recently closed a Series A to support its operations. Unite US is building a consumer‑facing platform that aggregates disparate veteran resources under one digital roof and uses interactive mapping and matching to connect users with organizations and peers. The company was founded by three members of the Armed Forces and is led by co‑founder and CEO Dan Brillman. Its product includes built‑in CRM tools for organizations to manage membership and collaborate, and a matchmaking/discovery approach that the team likens to Yelp and match.com rather than a professional network. The startup says roughly 10% of the product is focused on professional/job facilitation. Unite US is for‑profit and intends to partner with companies that value visibility and access among veterans. It is partly in stealth with a public launch planned for this fall and has raised initial outside capital to support development.

No current team members are available.